Search

Alkermes PLC

Geschlossen

BrancheGesundheitswesen

49.21 0.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

48.37

Max

49.46

Schlüsselkennzahlen

By Trading Economics

Einkommen

67M

501K

Verkäufe

103M

496M

KGV

Branchendurchschnitt

131.184

57.371

EPS

0.52

Gewinnspanne

0.101

Angestellte

2,050

EBITDA

76M

54M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.19% upside

Dividenden

By Acuity

Nächstes Ergebnis

27. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-426M

8.4B

Vorheriger Eröffnungskurs

48.33

Vorheriger Schlusskurs

49.21

Nachrichtenstimmung

By Acuity

10%

90%

6 / 340 Ranking in Healthcare

Alkermes PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

20. Aug. 2026, 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

19. Aug. 2026, 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

18. Aug. 2026, 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

17. Aug. 2026, 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

14. Aug. 2026, 19:46 UTC

Alkermes Plc shares are lower today amid broader market weakness following a reported decline in U.S. retail sales for July.

13. Aug. 2026, 19:26 UTC

Alkermes Plc shares are lower during Thursday's session, breaking a trend of higher closes. Broader market sentiment may be influenced by rising jobless claims.

12. Aug. 2026, 21:51 UTC

Alkermes shares are higher in after-market trading, reflecting positive momentum amid easing inflation concerns and a broader market recovery.

11. Aug. 2026, 19:26 UTC

Alkermes Plc shares are trading lower today, remaining near the lower end of their one-month range amid a lack of specific company news.

10. Aug. 2026, 19:46 UTC

Alkermes shares are advancing today, despite earlier fluctuations and no specific news. Broader market uncertainty follows a decline in U.S. employment reported last Friday.

6. Aug. 2026, 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5. Aug. 2026, 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4. Aug. 2026, 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3. Aug. 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31. Juli 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30. Juli 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29. Juli 2026, 20:03 UTC

News
Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28. Juli 2026, 20:02 UTC

News
Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24. Juli 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22. Juli 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21. Juli 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20. Juli 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Peer-Vergleich

Kursveränderung

Alkermes PLC Prognose

Kursziel

By TipRanks

19.19% Vorteil

12-Monats-Prognose

Durchschnitt 58.25 USD  19.19%

Hoch 65 USD

Tief 38 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alkermes PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

9

Buy

2

Halten

1

Sell

Stimmung

By Acuity

6 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat